TABLE 4

Performance of genotypic generalized linear models for prediction of phenotypic antibiotic resistance in E. coli, K. pneumoniae, P. mirabilis, and P. aeruginosa

Bacterium and antibioticSensitivity (%)Specificity (%)% agreement (95% CIa)PPV (%)NPV (%)
E. coli (n = 2,919)
    Aztreonam948390 (89–91)9286
    Cefazolin909191 (90–92)9777
    Cefepime889189 (88–90)9579
    Cefotaxime939292 (91–93)9684
    Ceftazidime808381 (80–83)8677
    Ceftriaxone949193 (92–94)9686
    Ciprofloxacin959194 (93–95)9690
    Levofloxacin969094 (93–95)9593
    Gentamicin879592 (91–93)9093
    Tobramycin919392 (91–93)9192
    Trimethoprim-sulfamethoxazole908889 (88–90)9286
    Piperacillin958894 (93–95)9872
K. pneumoniae (n = 1,974)
    Aztreonam878586 (85–88)9754
    Cefazolin100090 (88–91)90NAb
    Cefepime888588 (86–89)9757
    Cefotaxime908689 (88–90)9856
    Ceftazidime887786 (85–88)9555
    Ceftriaxone898589 (87–90)9855
    Ciprofloxacin938091 (89–92)9573
    Levofloxacin898187 (95–88)9274
    Imipenem858887 (85–88)8290
    Gentamicin848986 (84–87)9180
    Tobramycin908689 (88–91)9574
    Trimethoprim-sulfamethoxazole947289 (87–90)9180
P. mirabilis (n = 1,150)
    Ampicillin839486 (84–88)9768
    Cefazolin836373 (70–75)6879
    Cefotaxime839490 (88–91)9089
    Ceftazidime739489 (88–91)7893
    Ceftriaxone839489 (87–90)9188
    Gentamicin789588 (86–90)9186
    Tobramycin699685 (83–87)9183
    Trimethoprim-sulfamethoxazole878285 (83–87)8979
    Piperacillin898888 (86–90)9284
P. aeruginosa (n = 1,484)
    Ciprofloxacin868284 (82–86)9174
    Levofloxacin838182 (80–84)9169
  • a CI, confidence interval.

  • b NA, not available.